Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Depotech(depo) -- Ignore unavailable to you. Want to Upgrade?

To: seminole who wrote (704)	2/3/1998 10:14:00 PM
From: Czechsinthemail	Read Replies (2) \| Respond to of 887

richard, Thanks for the article. It looks pretty chaotic for DEPO at the moment. It is hard enough having to scramble to reorganize the company after the negative ODAC news, but having to add a major executive reorganization on top of it doesn't sound good. Also not good, IMHO, is that DEPO apparently hasn't yet had the conversation with the FDA that supposedly was going to occur in January regarding how to proceed on DepoCyt. Though I think DEPO has a strong technology to work with, their ability to make it work has some big question marks in the picture. Unless they can come up with a major partnership or a surprise on DepoCyt, I'm afraid the money will run out and/or the company will go into a death spiral of private placements with the stock price depressed. Of course, there is the possibility that the board's new plan will be to sell the company. I wonder what kind of deal they could cut? Baird